Question 1

How big is the intravenous immunoglobulin market?

Accepted Answer

Intravenous immunoglobulin (IVIG) industry size was USD 10.9 billion in 2022 and is projected to exhibit 7.6% CAGR from 2023 to 2032 attributed to the high prevalence of primary immunodeficiency disorders and secondary immunodeficiencies worldwide.

Question 2

Which are the leading firms operating in the intravenous immunoglobulin industry?

Accepted Answer

Some of the major companies in the intravenous immunoglobulin industry are Takeda Pharmaceutical Company Limited., Grifols SA, ADMA Biologics, Octapharma AG, Baxter International Inc., LFB Biotechnologies, China Biologics Products Inc., Kedrion Biopharma, and Intas Pharmaceuticals.

Question 3

Why is the demand for the IgG gaining traction?

Accepted Answer

The IgG segment is poised to record significant growth through 2032 driven by its remarkable versatility, which encompasses a diverse array of functions within the immune system.

Question 4

What is the size of the North America intravenous immunoglobulin industry?

Accepted Answer

North America held 52.3% share of the IVIG market in 2022 and is anticipated to grow at 7.7% CAGR from 2023 to 2032 owing to the high prevalence of immune-mediated diseases, autoimmune disorders, and primary immunodeficiency diseases.

Intravenous Immunoglobulin Market Share

Intravenous Immunoglobulin Market Share

Premium Report Details

Industries

Information

Link

Global Headquarters